

Abel D. Jarell, MD, FAAD
Adjunct Clinical Professor, Dartmouth School of Medicine
Medical Director & Chief Investigator, ALLCUTIS Research, LLC.
CEO & Founder, Principal Investigator, StracSkin, PLLC.
jarell@post.harvard.edu / ajtrials@stracskin.com / ajarell@stracskin.com
(mobile) 617-833-9995 (office) 603-651-9177

95 Brewery Lane, Suite 5, 1st Floor
Portsmouth, NH 03801

215 Commerce Way, Suite 100
Portsmouth, NH 03801

Education & Selected Honors

U.S. Military Academy, West Point, NY (1993)

Bachelor of Science (B.S.) in Chemistry, Mechanical Engineering minor, Physical Education minor

- ◆ Distinguished Cadet (top 5% in class academically)
- ◆ Superintendent's Award (Superior Achievement in Academics, Leadership and Physical Fitness)
- ◆ West Point Outstanding Achievement in Mathematics Recognition Award (1990)

Harvard Medical School, Boston, MA

Doctor of Medicine (1998)

- ◆ Recipient of NIH Pre-doctoral Research Fellowship
- ◆ AMA/Glaxo Welcome National Achievement/Leadership Delegate

Post-Graduation Education

Internship – General Surgery, 7/98 – 6/99

University of Washington, Department of Surgery, Seattle, WA

Residency – Dermatology, 7/06 – 6/09

Harvard Medical School, Department of Dermatology, Boston, MA

Chief Resident, 7/08 – 6/09

Fellowship – Dermatopathology, 7/09 – 7/10

University of California (UCSF), Department of Dermatopathology, San Francisco, CA

Board Certifications

Dermatology: American Board of Dermatology, 2009, Recertified 2019

Dermatopathology: American Board of Dermatology, 2010, Recertified 2019

Medical Licenses

Maryland – current, active, unrestricted (D0073683)

New Hampshire – current, active, unrestricted (15251)

Selected Leadership Positions

4/2017 – 4/2020	President, New Hampshire Society for Dermatology
4/2016 – 4/2017	Secretary, New Hampshire Society for Dermatology
3/2018 – 2021	Voting Member, Am. Acad. of Dermatology Healthcare & Finance Committee
3/2016 – present	Voting Member, Am. Acad. of Dermatology, Leadership Committee
3/2022 – present	Voting Member, Am. Acad. of Dermatology, Diversity Committee

Experience & Positions Held

3/2025 – present	<i>Dermatologist & Dermatopathologist</i> Optima Dermatology Portsmouth, NH
5/2022 – present	<i>Owner, Chief Investigator, Consultant</i> StracSkin, PLLC Strategic Trials, Research and Consulting in Skin Portsmouth, NH
6/2019 – present	<i>Medical Director, Chief Investigator</i> ALLCUTIS Research, LLC., Center for Understanding Therapeutics in Skin Portsmouth, NH
3/2016 – present	<i>Principal Investigator</i> ActivMed Practices & Research, LLC. Portsmouth, NH
3/2015 – 2/2025	<i>Dermatologist & Dermatopathologist</i> Northeast Dermatology Associates (NEDA) Portsmouth, NH
7/2010 – 1/2015	<i>Assistant Professor of Dermatology & Dermatopathology</i> Walter Reed National Military Medical Center Uniformed Services University of the Health Sciences Bethesda, MD
	<ul style="list-style-type: none"> ◆ Chief, Dermatopathology, Dermatology Section, Department of Medicine ◆ Director, Walter Reed & Murtha Cancer Center Melanoma and Pigmented Lesion Clinic ◆ Associate Program Director, Walter Reed Dermatopathology Fellowship ◆ Cancer Liaison Physician for Walter Reed to the American College of Surgeons ◆ Head of the Dermatology visitor, medical student and intern/resident rotators ◆ Scientific Review Committee Member, Walter Reed Bethesda ◆ Quality Assurance Officer, Department of Dermatology ◆ Winner of 1st Place, Association of Military Dermatologists Staff Research Award (2012) ◆ Winner of 3rd Place, Association of Military Dermatologists Staff Research Award (2014) ◆ Delegate to the American Academy of Dermatology Academic Dermatology Leadership Program (ADLP)

Experience & Positions Held Continued

- 8/2011 – 2/2015 ***Staff Dermatologist & Dermatopathologist***
Saco River Medical Group
Conway, NH

Work as dermatologist and dermatopathologist in under-served White Mountains / Mt. Washington Valley region of NH. Perform all duties of general dermatologist and dermatopathologist, approximately 2 full days per month.
- 1/2011 – 6/2011 ***Squadron Surgeon & General Medical Officer***
2nd Cavalry Regiment / 4th Squadron
Kandahar Province and Arghandab River Valley, Afghanistan

Squadron staff officer, consultant to the commander. Deployed to Afghanistan in support of Operation Enduring Freedom. Duties include overall responsibility for health and welfare of squadron and all forward operating base personnel (approx. 1,100).
- 7/2003 – 8/2004 ***Brigade Surgeon & General Medical Officer***
3rd Brigade/1st Armor Division
Ft. Riley, KS
- 8/2004 – 5/2006 ***Brigade Staff Officer, Consultant to Commander***
1st Brigade/1st Infantry Division
Ft. Riley, KS

Deployed to Iraq in support of Operation Iraqi Freedom. Duties include overall responsibility for health and welfare of Brigade Combat Team (approx. 4,500 soldiers), primary care medical management, preventive medicine, supervision of five physician assistants and combat readiness for brigade. Senior medical officer in combat theatre of operations, overseeing additional six physicians. Supervise technical training of medical personnel. Monitor and supervise aeromedical and ground ambulance evacuation (MEDEVAC). Recipient of the Combat Medical Badge for performance of medical duties while under fire during combat operations. Recipient of the Meritorious Service Medal and nominated for the Bronze Star Medal.
- 1/2001 – 7/2002 ***Graduate Student & Research Assistant***
Neurosurgery / Neurology National Capital Neurotrauma Research Laboratory
Bethesda, MD

Laboratory of Drs. James Ecklund and Geoffrey Ling. Conducted research directed toward the elucidation of cellular and molecular mechanisms involved in traumatic brain injury.

Experience & Positions Held Continued

6/1999 – 1/2001 ***Post-Doctoral Research Fellow, Drs. Richard S. Morrison and Michael Bobola***
University of Washington and Children's Hospital, Dept. of Neurological Surgery
Seattle, WA

3/1994 – 4/1998 ***NIH Predoctoral Research Assistant, Dr. Jeffrey D. Macklic***
Children's Hospital & Harvard Medical School Program in Neuroscience
Boston, MA

Principal Investigator Clinical Research Trial Experience

2015

Eli Lilly	Phase 3, Moderate to Severe Plaque Psoriasis
Braintree	Phase 3, Topical Treatment for Moderate to Severe Facial Acne
Cutanea Life Sciences	Phase 2, Topical Gel for Females with Moderate to Severe Facial Acne
Dermira	Phase 3, Moderate to Severe Plaque Psoriasis, Certolizumab Pegol
Eli Lilly	Phase 3, Moderate to Severe Plaque Psoriasis, SC injection
Regeneron	Phase 3, Moderate to Severe Atopic Dermatitis, Dupilumab SC injection

2016

Par Pharmaceuticals	Phase 3, Mild to Moderate Atopic Dermatitis
Sol-Gel	Phase 2, Topical Treatment for Facial Acne

2017

Athenex	Phase 3, Topical Treatment for Actinic Keratosis
Cellceutix	Phase 3, Moderate to Severe Plaque Psoriasis, Oral Treatment
Cutanea Life Sciences	Phase 3, Common Warts
Foamix	Phase 3, Moderate to Severe Acne
Incyte Corporation	Phase 2, Vitiligo, Topical Treatment
RXi Pharmaceuticals	Phase 2, Common Warts, Samcyprone Ointment
UCB	Phase 3, Moderate to Severe Plaque Psoriasis, SC injection (PS0009)

2018

AbbVie, Inc.	Phase 3, Moderate to Severe Atopic Dermatitis in Adolescents & Adults
Asana Biosciences	Phase 2, Moderate to Severe Atopic Dermatitis, Oral Treatment
Incyte Corporation	Phase 3, Atopic Dermatitis, Topical Treatment
Trevi Pharmaceuticals	Phase 2b/3, Prurigo Nodularis, ER Nalbuphine
UCB	Phase 3, Moderate to Severe Plaque Psoriasis, SC injection (PS0013)
UCB	Phase 3, Moderate to Severe Plaque Psoriasis, SC injection (PS0014)
UCB	Phase 3, Moderate to Severe Plaque Psoriasis, SC injection (PS0015)
Asana Biosciences	Phase 2b, Moderate to Severe Atopic Dermatitis, Open-Label Extension
Bristol Myers Squibb	Phase 3, Moderate to Severe Plaque Psoriasis, SC injection
Celgene Corporation	Phase 3, Moderate to Severe Genital Psoriasis, Oral Treatment
Dermira	Phase 2b, Moderate to Severe Atopic Dermatitis, Lebrikizumab
Eli Lilly	Phase 4, Moderate to Severe Plaque Psoriasis, SC injection

Principal Investigator Clinical Research Trial Experience (Continued)

2019

AbbVie, Inc.	Phase 3, Risankizumab Autoinjector for Psoriasis
Arcutis, Inc.	Phase 3, Mild to Moderate Plaque Psoriasis, Topical Treatment
Asana Biosciences	Phase 2, Moderate to Severe Hand Eczema
Concert Pharmaceuticals	Phase 2, Moderate to Severe Alopecia Areata
Concert Pharmaceuticals	Phase 2, Moderate to Severe Alopecia Areata, Open-Label Extension
Dermira	Phase 3, Moderate to Severe Atopic Dermatitis, Lebrikizumab
Dermira	Phase 3, Moderate to Severe Atopic Dermatitis, Lebrikizumab/Topical Combo
Dermira	Phase 3, Moderate to Severe Atopic Dermatitis Adolescents, Lebrikizumab
Eli Lilly	Phase 2/3, Moderate to Severe Alopecia Areata, Baricitinib
Eli Lilly	Phase 1, Atopic Dermatitis, SC injection
Eli Lilly	Phase 1, Psoriasis, SC injection
Galderma	Phase 3b, Topical Treatment for Moderate to Severe Facial & Truncal Acne
Galderma	Phase 3, Topical Treatment for Actinic Keratosis
Novan, Inc.	Phase 3, Topical Treatment for Molluscum Contagiosum
UCB	Phase 3, Moderate to Severe Plaque Psoriasis, Adolescent & Pediatric, Cimzia
UCB	Phase 3, Moderate to Severe Hidradenitis Suppurativa, SC injection

2020

Amgen	Phase 3, Moderate to Severe Plaque Psoriasis, SC injection
AoBiome Therapeutics	Phase 2, Topical Spray for Pruritis in Adults with a History of Atopic Dermatitis
Arcutis, Inc.	Phase 3, Mild to Moderate Plaque Psoriasis, Topical Treatment, Open-Label Ext
Arcutis, Inc.	Phase 2b, Scalp and Body Psoriasis in Adolescents and Adults, Topical Treatment
Arcutis, Inc.	Phase 2, Topical Treatment for Seborrheic Dermatitis
AstraZeneca	Phase 2, Moderate to Severe Atopic Dermatitis, Benralizumab
Bellus Health	Phase 2, Oral Treatment for Chronic Pruritus in Adults with Atopic Dermatitis
Bristol Myers Squibb	Phase 3b, Moderate to Severe Plaque Psoriasis, SC injection, Extension Study
Dermira	Phase 3, Moderate to Severe Atopic Dermatitis, Lebrikizumab Open-Label Ext
Eli Lilly	Phase 2, Moderate to Severe Hidradenitis Suppurativa, SC injection
Galderma	Phase 3, Topical Treatment for Actinic Keratosis, Open-Label Extension
Galderma	Phase 2, Atopic Dermatitis in Adolescents and Adults, SC injection
Nimbus Lakshmi, Inc.	Phase 1, Oral Treatment for Moderate to Severe Plaque Psoriasis

2021

Amgen	Phase 3, Moderate to Severe Plaque Psoriasis, SC injection
AnaptysBio	Phase 2, Hidradenitis Suppurativa, SC injection
AnaptysBio	Phase 2, Acne Vulgaris, SC injection
Arcutis, Inc.	Phase 1, Topical Treatment for Scalp and Body Psoriasis in Adolescents and Adults
Aristea Therapeutics, Inc.	Phase 2, Palmoplantar Pustulosis, Oral Treatment
Dong-A ST Co., Ltd.	Phase 3, Oral Treatment for Moderate to Severe Chronic Plaque Psoriasis
Janssen Research	Phase 2a/2b, Moderate to Severe Hidradenitis Suppurativa, SC injection
Incyte Corporation	Phase 2, Oral Treatment for Prurigo Nodularis
Leo Pharmaceuticals	Phase 3, Moderate to Severe Atopic Dermatitis, SC injection
Skin Analytics	A Validation Study to Identify Skin Cancer using Artificial Intelligence Algorithm
UCB	Phase 3, Moderate to Severe Hidradenitis Suppurativa, SC injection, Extension
Union Therapeutics	Phase 2b, Moderate to Severe Plaque-Type Psoriasis, Oral Treatment

Principal Investigator Clinical Research Trial Experience (Continued)

2022

Almirall, S.A.	Phase 3, Actinic Keratosis in Adults, Topical Treatment
Alumis	Phase 2, Moderate to Severe Plaque Psoriasis, Oral Treatment
Amgen	Phase 3, Moderate to Severe Atopic Dermatitis, Oral Treatment
Amgen	Phase 3, Moderate to Severe Atopic Dermatitis in Adolescents, SC injection
Amgen	Phase 3, Moderate to Severe Atopic Dermatitis, SC injection
Bristol Myers Squibb	Phase 2, Moderate to Severe Psoriasis, Oral Treatment
Eli Lilly	Phase 3b, Moderate to Severe Atopic Dermatitis, SC injection
Eli Lilly	Phase 3b, Moderate to Severe Atopic Dermatitis in Skin of Color, SC injection
Incyte Corporation	Phase 3, Moderate to Severe Hidradenitis Suppurativa, Oral Treatment
Janssen Research	Phase 2a, Moderate to Severe Plaque Psoriasis, Oral Treatment
Janssen Research	Analytical Validation Study for Nocturnal Scratch in Atopic Dermatitis
Pfizer	Phase 2/3, Moderate to Severe Atopic Dermatitis, Oral Treatment
Suzhou Kintor	Phase 2, Androgenetic Alopecia in Male Subjects, Topical Treatment
Union Therapeutics	Phase 2b, Moderate to Severe Atopic Dermatitis, Oral Treatment
Ventyx Biosciences	Phase 2, Moderate to Severe Psoriasis, Oral Treatment

2023

AbbVie, Inc.	Phase 3, Moderate to Severe Atopic Dermatitis in Adolescents/Adults, Combo
Alumis	Phase 2, Open-Label Ext for Moderate to Severe Plaque Psoriasis, Oral Treatment
Cara Therapeutics	Phase 2/3, Moderate to Severe Pruritus in Adults, Oral Treatment
DICE Therapeutics, Inc.	Phase 2b, Moderate to Severe Plaque Psoriasis, Oral Treatment
Eli Lilly	Phase 2, Moderate to Severe Atopic Dermatitis in Adults, Multiple Interventions
Eli Lilly	Phase 2, Moderate to Severe Atopic Dermatitis in Adults, SC injection
Eli Lilly	Phase 2b, Moderate to Severe Hidradenitis Suppurativa, SC injection
Incyte Corporation	Phase 3, Prurigo Nodularis, Topical Treatment
Incyte Corporation	Phase 3, Nonsegmental Vitiligo in Adults, Oral Treatment
Incyte Corporation	Phase 3, Hidradenitis Suppurativa in Adults, Oral Treatment
Janssen Research	Phase 3, Moderate to Severe Plaque Psoriasis in Adolescents/Adults, Oral Treatment
Janssen Research	Phase 3, Moderate to Severe Plaque Psoriasis in Adults, Oral Treatment
Leo Pharmaceuticals	Phase 3b, Moderate to Severe Hand Eczema, SC injection
Sanofi-Aventis	Phase 3, Moderate to Severe Atopic Dermatitis in Adults, SC injection
Takeda Pharmaceuticals	Phase 3, Moderate to Severe Plaque Psoriasis in Adults, Oral Treatment
Takeda Pharmaceuticals	Phase 3, Moderate to Severe Plaque Psoriasis in Adults, Oral Treatment
Verrica Pharmaceuticals	Phase 2, Basal Cell Carcinoma in Adults, SC injection

2024

AbbVie, Inc.	Phase 3, Moderate to Severe Hidradenitis Suppurativa in Adults and Adolescents
Avalo	Phase 2, Moderate to Severe Hidradenitis in Adults, SC injection
Castle Biosciences	Inflammatory Skin Disease Treatment Identification Study
Eli Lilly	Phase 2a, Moderate to Severe Hidradenitis Suppurative in Adults, SC injection
Eli Lilly	Phase 3b, Moderate to Severe Plaque Psoriasis and Obesity, SC Injection
Eli Lilly	Phase 4, Nail and Scalp Psoriasis Improvement in Patients Treated with Ixekizumab
Incyte Corporation	Phase 3, Moderate to Severe Prurigo Nodularis in Adults, Oral Treatment
Incyte Corporation	Phase 3, Nonsegmental Vitiligo in Pediatric Participants, Topical Treatment
Leo Pharmaceuticals	Phase 4, Observational Study of Atopic Dermatitis Patients Prescribed Tralokinumab
Takeda Pharmaceuticals	Phase 3, Moderate to Severe Plaque Psoriasis in Adults, Oral Treatment

Principal Investigator Clinical Research Trial Experience (Continued)

2025

Arcutis, Inc.	Phase 4, Mild to Moderate Atopic Dermatitis in Infants Using Topical Roflumilast
CorEvitas	International Adolescent Alopecia Areata Drug Safety and Effectiveness Registry
Eli Lilly	Phase 4, Moderate to Severe Atopic Dermatitis in Adult & Pediatric, Lebrikizumab
Eli Lilly	Phase 4, Moderate to Severe Psoriasis & Obesity Patients, Ixekizumab & Tirzepatide

Publications

Original Articles and Case Reports

- Stein Gold L, Lewitt GM, Lockshin B, et al. and Jarell AD (Senior author). (2024) Tapinarof Cream 1% Once Daily is Efficacious in the Treatment of Mild to Severe Plaque Psoriasis in the Head and Neck Region. *Skin*. Vol 8(2).
- Bhatia N, Lain E, Jarell AD, et al. (2023) Safety and tolerability of tirbanibulin ointment 1% treatment on 100 cm² of the face or scalp in patients with actinic keratosis: A phase 3 study. *JAAD International*. 2024. Accepted for publication.
- Witkowski A, Jarell AD, Kelli AL, et al. (2024) A clinical impact study of dermatologists' use of diagnostic gene expression profile testing to guide patient management. *Melanoma Management*. APR2024 11(1).
- Jarell AD, Lewitt GM, Serrao R, et al. (2024) Early improvement in nail, scalp, and skin psoriasis with ixekizumab – PSoSA Study first interim results. Submitted to *J Drugs Dermatol*. 2024.
- Jarell AD (2022) A Physician's Guide to the Use of Gene Expression Profile Ancillary Diagnostic Testing for Cutaneous Melanocytic Neoplasms. Submitted to *Journal of Clinical and Aesthetic Dermatology*.
- Jarell AD, Gastman BR, Dillon LD, et al. (2022) Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test. Accepted *JAAD*.
- Dillon LD, McPhee M, Davidson RS, Jarell AD, et al. (2022) Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study. *Curr Med Res Opin*. Jan 27:1-21. 1267-1274.
- Jarell A, Skenderis B, Dillon LD, et al. (2021) The 31-gene expression profile stratifies recurrence and metastasis risk in patients with cutaneous melanoma. *Future Oncol*. Dec;17(36):5023-5031.
- Porter C, Riddle S, Jarell AD (2020) A first in human clinical trial assessing the safety and immunogenicity of transcutaneously delivered enterotoxigenic *Escherichia coli* fimbrial tip adhesin with or without heat-labile enterotoxin with mutation R192G. *Vaccine*. Oct;38(45):7040-7048.
- Gutierrez R, Porter CK, Jarell AD, et al. (2020) A grading system for local skin reactions developed for clinical trials of an intradermal and transcutaneous ETEC vaccine. *Vaccine*. 6;38(21):3773-3779.
- Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J; IXORA-R Study Group. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. *Br J Dermatol*. 2019 Dec 30. doi: 10.1111/bjd.18851. [Epub ahead of print]
- Dillon, LD, Gadzia JE, Jarell AD, et al. (2018) Prospective, Multicenter Clinical Impact Evaluation of a 31-Gene Expression Profile Test for Management of Melanoma Patients. *Skin*. 2(2).
- Wang B, Jarell AD, Bingham JL, and Bonavia GH. (2015) PET/CT Imaging of squamoid eccrine

Original Articles and Case Reports (continued)

- Hoverson K, Jarell AD, Wohltmann W. (2017) Lupus erythematosus tumidus of the scalp masquerading as alopecia areata. Cutis. 2017 February;99(2): E22-E24.
- Morgan MK, Whitman TJ, Cohen JI, Mitchum MD, Jarell AD, Burgess TH. (2014) A patient with fever and rash. Clin Infect Dis. 2014 Jul 1;59(1):95, 136-7.
- Oganessian G, Jarell AD, Srivastava M, Jiang SI. (2013) Efficacy and complication rates of full-thickness skin graft repair of lower extremity wounds after Mohs micrographic surgery. Dermatol Surg. Sep;39(9):1334-9.
- Jarell AD and McCalmont TH. (2012). Granular cell angiosarcoma. J Cutan Pathol. May;39(5):476-8.
- Jarell AD and Mully TM. (2012) Basal cell carcinoma of the ear is more likely to be of an aggressive phenotype in both men and women. Journal of the American Academy of Dermatology. May;66(5):780-4.
- Jarell AD, Dans MJ, Elston DM, et al. (2011) Gnathostomiasis in a patient who frequently consumes sushi. Am J Dermatopathol. Dec;33(8):91 - 93.
- Konnikov N, Avram M, Jarell AD, Tannous Z. (2011) Pulsed dye laser as a novel non-surgical treatment for basal cell carcinomas: response and follow up 12-21 months after treatment. Lasers Surg Med. Feb;43(2):72-8.
- Morgan EA, Henrich TJ, Jarell AD, Velazquez EF, et al. (2010) Infectious granulomatous dermatitis associated with *Rothia mucilaginosa* bacteremia: a case report. Am J Dermatopathol. 32(2):175 – 9
- Tucker JD, Shah S, Jarell AD, Tsai KY, Zembowicz A, Kroshinsky D (2009) Lues maligna in early HIV infection. Case report and review of the literature. Sex Transm Dis. 36(8):512 – 4.
- Jarell AD, Hall MA, Sperling LC (2007) Uncombable Hair Syndrome. Pediatric Dermatology. 2007 Jul- Aug;24(4):436-438.
- Jarell AD, Hall MA (2007) Swelling of the Right Ear. Am Fam Physician. 1;75(9):1379-1380.
- Kinoshita Y, Jarell AD, Morrison RS, et al. (2001) Pescadillo, A Novel Cell Cycle Regulatory Protein Abnormally Expressed in Malignant Cells. J Biol Chem. 276(9):6656-6665.
- Foltz, GD, Jarell AD, Schuster JS, Matsumura M, Farrell L, Nelson P, Silbergeld DL (2000) Identification and Characterization of VASP, a Motility-related Gene with Aberrant Expression in Glioblastoma. Neurosurgery. 47(2):518.
- Kuntz C IV, Mirza SK, Jarell AD, Chapman JR, Shaffrey CI, Newell DW (2000) Type II Odontoid Fractures in the Elderly: Early Failure of Nonsurgical Treatment. Neurosurgical Focus 8(6):7 2000.

Reviews

- Jarell AD, Kimball AB (2009 with updates in annually, most recent 2022) Rosacea. Brit Med J. Online publication.

- Jarell AD, Lawrence D, Tsao H (2007) The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics. *Biologics*. 1(4):407-414.
- Temkin NR, Jarell AD, Anderson GD (2001) Antiepileptogenic Agents: How Close are We? *Drugs*. 61(8):1045-1055.
- Soltesz EG, Jarell AD, Black PM, et al. (1999) Radiation Therapy for Gliomas. *Crit Rev. Neurosurg*. 9:376-386.

Book Chapters

- Jepperson S and Jarell AD (2014) Ticks. Chapter in: *Manual of Dermatologic Therapeutics*, 8th Ed. Eds. Arndt, Hsu, Alam, et al. Lippincott.
- Jepperson S and Jarell AD (2014) Sunburn. Chapter in: *Manual of Dermatologic Therapeutics*, 8th Ed. Eds. Arndt, Hsu, Alam, et al. Lippincott.
- Kim D and Jarell AD (2014) Burns. Chapter in: *Manual of Dermatologic Therapeutics*, 8th Ed. Eds. Arndt, Hsu, Alam, et al. Lippincott.
- Buikema K and Jarell AD (2014) Dermatophytosis. Chapter in: *Manual of Dermatologic Therapeutics*, 8th Ed. Eds. Arndt, Hsu, Alam, et al. Lippincott.
- Jarell, AD (2012) Nodular fasciitis. Chapter in: *Horvai: Bone and Soft Tissue Pathology*. Ed. A. Horvai. Elsevier. Philadelphia. 194-196.
- Jarell, AD (2012) Proliferative myositis and proliferative fasciitis. Chapter in: *Horvai: Bone and Soft Tissue Pathology*. Ed. A. Horvai. Elsevier. Philadelphia. 197-198.
- Jarell, AD (2012) Ischemic fasciitis. Chapter in: *Horvai: Bone and Soft Tissue Pathology*. Ed. A. Horvai. Elsevier. Philadelphia. 199-200.
- Jarell, AD (2012) Postoperative spindle cell nodule. Chapter in: *Horvai: Bone and Soft Tissue Pathology*. Ed. A. Horvai. Elsevier. Philadelphia. 201-202.
- Jarell, AD (2012) Necrotizing fasciitis. Chapter in: *Horvai: Bone and Soft Tissue Pathology*. Ed. A. Horvai. Elsevier. Philadelphia. 203-204.
- Jarell, AD (2012) Elastofibroma. Chapter in: *Horvai: Bone and Soft Tissue Pathology*. Ed. A. Horvai. Elsevier. Philadelphia. 205-206.
- Jarell, AD (2012) Desmoplastic fibroblastoma. Chapter in: *Horvai: Bone and Soft Tissue Pathology*. Ed. A. Horvai. Elsevier. Philadelphia. 207-208.
- Jarell, AD (2012) Hypertrophic scar. Chapter in: *Horvai: Bone and Soft Tissue Pathology*. Ed. A. Horvai. Elsevier. Philadelphia. 209-210.
- Jarell, AD (2012) Keloid. Chapter in: *Horvai: Bone and Soft Tissue Pathology*. Ed. A. Horvai. Elsevier. Philadelphia. 211.
- Jarell, AD (2012) Fibrous hamartoma of infancy. Chapter in: *Horvai: Bone and Soft Tissue Pathology*. Ed. A. Horvai. Elsevier. Philadelphia. 212-213.
- Jarell, AD (2012) Gardner fibroma. Chapter in: *Horvai: Bone and Soft Tissue Pathology*. Ed. A. Horvai. Elsevier. Philadelphia. 214-215.
- Jarell, AD (2012) Nuchal fibroma. Chapter in: *Horvai: Bone and Soft Tissue Pathology*. Ed. A. Horvai. Elsevier. Philadelphia. 216.
- Jarell, AD (2012) Fibromatosis colli. Chapter in: *Horvai: Bone and Soft Tissue Pathology*. Ed. A. Horvai. Elsevier. Philadelphia. 217-218.
- Jarell, AD (2012) Calcifying aponeurotic fibroma. Chapter in: *Horvai: Bone and Soft Tissue Pathology*. Ed. A. Horvai. Elsevier. Philadelphia. 219-220.
- Jarell, AD (2012) Fibroma of tendon sheath. Chapter in: *Horvai: Bone and Soft Tissue Pathology*.

- Ed. A. Horvai. Elsevier. Philadelphia. 221-222.
- Jarell, AD (2012) Superficial fibromatosis. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 223-224.
 - Jarell, AD (2012) Deep fibromatosis. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 225-227.
 - Jarell, AD (2012) Inclusion-body fibroma. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 228-229
 - Jarell, AD (2012) IgG4-related sclerosing disease. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 230-231.
 - Jarell, AD (2012) Giant cell fibroblastoma. Chapter in: Horvai: Bone and Soft Tissue Pathology. Ed. A. Horvai. Elsevier. Philadelphia. 264-265.

Book Chapters (Continued)

- Jarell AD, Schalock PS (2010) Procedures in Dermatologic Diagnosis and Therapy. Chapter in: Primary Care Dermatology. Eds. PC Schalock, J Hsu, and K Arndt. Philadelphia: Lipincott Williams & Wilkins. 20 – 27.
- Jarell AD, Ecklund JM, Ling GS (2001) Traumatic Brain Injury. Chapter in: Combat Medicine. Executive Ed. GC Tsokos. New York: Humana Press. 351-370.
- Morrison RS, Jarell AD, Schuster JM (2003) Growth Factors and Brain Tumors. Chapter in: Youman's Neurological Surgery. 5th Ed. Executive Ed. HR Winn. Philadelphia: Saunders. 725-738.
- Riechers RG, Jarell AD, Ling GS (2004) Infections of the Central Nervous System. Chapter in: Critical Care Neurology and Neurosurgery. Executive Ed. JI Suarez. New York: Humana Press. 515-532.

Audio Publications and Interviews

- Jarell AD interviewed by DermTube. Shedding Light on the Darkness. DermTube video interview. Publication of the American Academy of Dermatology. July 2018.
- Jarell AD interviewed by DermTube. Build a Better Relationship with your Dermatopathologist. DermTube video interview (<https://dermtube.com/series/meeting-coverage-orlando-2017-mar/build-a-better-relationship-with-your-dermatopathologist/>). Publication of the American Academy of Dermatology. March 2017.
- Jarell AD interviewed by Kouroush AS. Help Your Dermatopathologist Work Smarter for You. Dialogues in Dermatology. Publication of the American Academy of Dermatology. April 2015.

Abstracts and Presentations

- Ameen A, Becherel P, Rubin C, Jarell A, et al. (2025) Patient-reported outcomes evaluations of 12-months tralokinumab treatment in 824 adults with atopic dermatitis: Real-world data from the prospective, non-interventional, international, single-cohort TRACE study. EADV, Paris, France, 9-2025.

- King B, Kempers S, Jarell A, et al. (2024) Optimization of deuroxolitinib dosing in adult patients with alopecia areata: results from a randomized, double-blind, multicenter, Phase 2 trial. EADV, Amsterdam, The Netherlands, 9-2024.
- Hasanov M, et al., Jarell A (senior author) (2024) The 31-GEP identifies patients with localized cutaneous melanoma at the highest risk of metastasis to the central nervous system. Presented at ASCO 2024.
- Stein Gold L, Lewitt, GM, Lockshin B, et al. and Jarell A (senior author). (2024) Tapinaroff cream 1% daily is efficacious in the treatment of mild to severe plaque psoriasis in the head and neck region. Presented at Winter Clinical Maui Derm 2024.
- Jarell A, Serrao R, Browne C, et al. (2024) Rapid response on psoriasis itch, scalp and nail pain, and quality of life from the interim analysis of the PSoriasis Special Areas (PSoSA) Observational study. Presented at Maui Derm Hawaii 2024.

Abstracts and Presentations (continued)

- Liu CM, Ezra N, et al, Jarell A. (2024) Effectiveness of ixekizumab on skin, nail and scalp clearance and improvement in quality of life in patients treated with ixekizumab: first interim analysis from an observational study of psoriasis special areas (PSoSA). Presented at Maui Derm Hawaii 2024.
- Soung J, Laquer V, Jarell A, et al. (2023) Lebrikzumab does not impact vaccine-induced immune responses: Results from a phase 3 study in adult patients with moderate-to-severe atopic dermatitis. Presented by Dr. Abel Jarell at International Society for Investigative Dermatology (ISID) annual meeting. Tokyo, Japan.
- Bhatia N, Blauvelt A, Lin E, Jarell A, et al. (2023) Safety and tolerability of tirbanibulin ointment 1% over a large field (up to 100 cm²) in actinic keratosis: A phase III study. Abstract ID 43739. Presented at American Academy of Dermatology annual meeting. New Orleans, LA.
- Jarell AD, Martin B, Prieto P. (2022) The integrated 31-gene expression profile (i31-GEP) test for cutaneous melanoma outperforms CP-GEP at identifying patients who can safely forego sentinel lymph node biopsy. Presented at Fall Clinical Conference. Las Vegas.
- Jarell AD, Mart B, Prieto P (2022) The integrated 31-gene expression profile (i31-GEP) test for cutaneous melanoma outperforms a clinicopathologic-only nomogram at identifying patients who can safely undergo a sentinel lymph node biopsy Presented at Fall Clinical Conference. Las Vegas.
- Jarell AD (2022) The 31-gene expression profile test stratifies risk of recurrence in patients with T1 melanoma. Presented at American Society for Dermatology. Oral presentation. Denver.
- Ludzik J, Witkowski A, Jarell AD et al. (2022) Clinical utility and a guide for using gene expression profile ancillary diagnostic testing for cutaneous melanocytic neoplasms. Presented at the Maui Derm NP/PA Fall Clinical Meeting. Las Vegas.
- Martin B, Morgan-Linnell SK, Jarell AD (2022) A pooled analysis of 894 Medicare-eligible patients: performance of the cutaneous melanoma 31-GEP risk-stratification test. Presented at the Society of Investigative Dermatology Annual Meeting.
- Jarell AD, Morgan-Linnell SK, Martin B, et al. (2022) The 31-Gene expression profile stratifies the risk of recurrence in patients with T1 cutaneous melanoma. Presented at the Society for

- Dermatology Physician Assistants annual meeting.
- Jarell AD, Skenderis B, Dillon LD, et al. (2022) The 31-Gene Expression Profile Stratifies Recurrence and Metastasis Risk in Patients with Cutaneous Melanoma. Presented at the American Academy of Dermatology Meeting, Boston, 3/22.
 - Jarell AD (2022) Help Your Dermatopathologist Work Smarter for You. Presented at the American Academy of Dermatology Meeting, Boston, 3/22.
 - Jarell AD, Smith S, Gallo G, et al. (2021) Ixekizumab Provides More Durable Improvements in Skin Clearance, Itch, and Quality of Life than Guselkumab in Patients with Moderate-to-Severe Psoriasis: 24-week Results from IXORA-R. Submitted for Presentation at AAD March 2021, San Francisco
 - Jarell AD (2020) Help Your Dermatopathologist Work Smarter for You. Presented at the American Academy of Dermatology Meeting, Denver, 3/20.

Abstracts and Presentations (continued)

- Blauvelt A, Kempers S, Forman S, Lain E, Bruce S, Ablon G, Jarell A, Bukhalo M, Liberman R, and Fang J. Tirbanibulin, a Novel Inhibitor of Tubulin Polymerisation and Src Kinase Signalling, for Actinic Keratosis: Results from two Phase III Studies. Eur Academy of Dermatology 2020.
- Jarell AD (2018) Shedding Light on the Darkness—Pigmented Lesions. Presented at the American Academy of Dermatology Meeting, Chicago, 7/18.
- Jarell AD (2018) Thin and Early Stage Melanoma. Presented at the Society for Dermatology Physician Assistants Annual Meeting by invitation, Seattle, WA.
- Jarell AD (2018) Locally Advanced and Metastatic Melanoma. Presented at the Society for Dermatology Physician Assistants Annual Meeting by invitation, Seattle, WA.
- Jarell AD (2017) Shedding Light on the Blackness—Pigmented Lesions. Presented at the American Academy of Dermatology Meeting, New York, 7/17.
- Jarell AD (2017) Help Your Dermatopathologist Work Smarter for You. Presented at the American Academy of Dermatology Meeting, Orlando, 3/17.
- Brady SP and Jarell AD (2015) Strappy Cells: A distinctive histological feature of and useful diagnostic clue in chondrodermatitis nodularis helices. Am Society of Dermatopathology Meeting, San Francisco, 10/15.
- Jarell AD (2014) Help your dermatopathologist work smarter for you. Podium-presented at American Academy of Dermatology Meeting, Chicago, 8/14.
- Gutierrez R, Riddle M, Porter C, Maciel M, Turiansky G, Jarell, A, Savarino S. (2013) Development and use of vaccine site grading scale for local vaccine site reactions after transcutaneous and intradermal vaccination with adhesin based ETEC vaccine candidates. Presented at the Vaccines for Enteric Diseases (VED) 2013 - Seventh International Conference, Bangkok, Thailand, 2013.
- Bhatia A, Hsu, J, Jarell AD, et al. (2012) The Chief Academy – Building a foundation for successful chief residents Our 5-year experience & planning for the future. Presented at the

Program Directors Annual Meeting, Chicago, 2012.

- Childs JC and Jarell AD. (2012). Papillary thyroid carcinoma metastatic to the skin. Presented at National Capital Consortium Research Day Symposium, 9 April 2012.
- Jarell AD and Mully TM. (2010) Basal cell carcinoma of the ear is more likely to be of an aggressive phenotype in both men and women. *Am Soc Dermatopathol. 2010.*
- Jarell AD, Dans MJ, Elston DM, et al. (2010) Gnathostomiasis in a patient who frequently consumes sushi. *International Soc Dermatopathol. 2010.*
- Jarell AD and McCalmont TH. (2010) Granular cell angiosarcoma: A rarity. *Am Soc Dermatopathol. 2009.*
- Konnikov N, Jarell AD, Tannous Z (2009) Response and recurrence rates of basal cell carcinomas treated with pulsed dye laser. *American Society for Laser Medicine and Surgery Annual Meeting, 2009.*
- Jarell AD, Srivastava M, Jiang B. (2007) Full thickness skin graft (FTSG) repair for lower extremity (below knee) tumors treated by Mohs Micrographic Surgery (MMS). *Mohs College Annual Meeting, 2007.*

Abstracts and Presentations (continued)

- Ling GSF, Riechers RG, Krishna PM, Blanchard J, Rosner M, Jarell AD, et al. (2002) Diagnosis of compartment syndrome using a microwave-based detector. *Proceedings of SPIE -- Volume 4744.*
- Jarell AD, Agoston DV, Ling GSF (2001) Expression of Pescadillo, a Novel Cell Cycle Regulator, in the Injured Rat Brain. *USUHS Neuroscience Research Day 2001. Abst.*
- Jarell AD, Foltz GD, Kinoshita Y, Morrison RS (2001) Pescadillo: Characterization of a Novel Cell Cycle Regulator Abnormally Expressed in Human Tumors. *Congress of Neurological Surgeons Annual Meeting, 2001. Abst.* (Recipient of CNS Overall 2nd Prize for Outstanding presentation).
- Foltz GD, Jarell AD, Schuster J, Matsamura M, et al. (2000) Identification and Characterization of VASP, a Motility- Related Gene with Aberrant Expression in Glioblastoma, using cDNA Microarrays. *Congress of Neurological Surgeons Annual Meeting, 2000. Abst.*
- Kuntz C IV, Jarell AD, Chapman JR, Shaffrey CI, Newell DW (1999) Odontoid Type 2 Fractures in the Elderly: Operative vs. Nonoperative Treatment. *Assoc. of American Neurological Surgeons Annual Meeting, 2000. Abst.*
- Jaramillo AD, Leavitt BR, Macklis JD (1997) Targeted Photolytic Apoptosis in Neuronal PC12 Cells is Dependent on New Protein Synthesis and Intrinsic Endonuclease Activity. *NIH Scientists, Tools, & Research for the 21st Century Abst.*
- Jaramillo AD, Leavitt BR, Macklis JD (1996) Targeted Photolytic Apoptosis in PC12 Cells is Dependent on Intrinsic Endonuclease Activity. *Soc. Neurosci. Abst.* 679.13.
- Jaramillo AD, Macklis JD (1995) Spatial and Temporal Characteristics of Microglia in Model of Selective Neuronal Degeneration. *Soma Weiss Abst.*
- Jaramillo AD, Sloop J (1993) Effect of Pyrazole Moiety on COS, CHO, CRL, and VERO Cell

